Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

2.

Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients.

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T.

Am J Respir Crit Care Med. 2018 Jun 7. doi: 10.1164/rccm.201711-2333OC. [Epub ahead of print]

PMID:
29877726
3.

Clofazimine for the Treatment of Mycobacterium kansasii.

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00248-18. doi: 10.1128/AAC.00248-18. Print 2018 Aug.

PMID:
29844047
4.

Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Apr 24. doi: 10.1093/cid/ciy346. [Epub ahead of print]

PMID:
29697766
5.

Pan-tuberculosis regimens: an argument against.

Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J.

Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3. No abstract available.

PMID:
29595502
6.

Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

Pasipanodya JG, Gumbo T.

Clin Infect Dis. 2018 Aug 16;67(5):717-718. doi: 10.1093/cid/ciy184. No abstract available.

PMID:
29514180
7.

Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance".

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02296-17. doi: 10.1128/AAC.02296-17. Print 2018 Mar. No abstract available.

8.

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, Gumbo T, McIlleron H.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):30-33. doi: 10.5588/ijtld.17.0475.

PMID:
29297422
9.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

10.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02232-17. doi: 10.1128/AAC.02232-17. Print 2018 Feb.

11.

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

PLoS One. 2017 Nov 2;12(11):e0187624. doi: 10.1371/journal.pone.0187624. eCollection 2017.

12.

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. Review.

PMID:
28922813
13.

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.

Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i54-i60. doi: 10.1093/jac/dkx309.

PMID:
28922811
14.

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.

Srivastava S, Deshpande D, Sherman CM, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i43-i47. doi: 10.1093/jac/dkx308.

PMID:
28922810
15.

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i48-i53. doi: 10.1093/jac/dkx307.

PMID:
28922809
16.

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.

Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i36-i42. doi: 10.1093/jac/dkx306.

PMID:
28922808
17.

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305.

PMID:
28922807
18.

Linezolid as treatment for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i24-i29. doi: 10.1093/jac/dkx304.

PMID:
28922806
19.
20.

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Deshpande D, Srivastava S, Chapagain M, Magombedze G, Martin KR, Cirrincione KN, Lee PS, Koeuth T, Dheda K, Gumbo T.

Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.

21.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
22.

pH Conditions under Which Pyrazinamide Works in Humans.

Srivastava S, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00854-17. doi: 10.1128/AAC.00854-17. Print 2017 Sep. No abstract available.

23.

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov.

24.

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

van Rijn SP, Srivastava S, Wessels MA, van Soolingen D, Alffenaar JC, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02039-16. doi: 10.1128/AAC.02039-16. Print 2017 Sep.

25.

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.

Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, Wakeland E, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00751-17. doi: 10.1128/AAC.00751-17. Print 2017 Aug.

26.

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.

Hall RG 2nd, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):552-559. doi: 10.1002/psp4.12208. Epub 2017 Jul 13.

27.

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

J Antimicrob Chemother. 2017 Jul 1;72(7):2020-2027. doi: 10.1093/jac/dkx111.

28.

Reply to Raoult.

Seddon JA, Makhene MK, Gumbo T.

Clin Infect Dis. 2017 Apr 1;64(7):984. doi: 10.1093/cid/cix038. No abstract available.

29.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
30.

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.

31.

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM.

Lancet Respir Med. 2017 Apr;5(4):269-281. doi: 10.1016/S2213-2600(16)30433-7. Epub 2017 Jan 19.

PMID:
28109869
32.

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.

33.

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

Br J Clin Pharmacol. 2017 Apr;83(4):801-811. doi: 10.1111/bcp.13172. Epub 2016 Dec 9.

34.

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.

Gumbo T, Makhene MK, Seddon JA.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S110-S115. Review.

35.

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.

Srivastava S, Deshpande D, Pasipanodya J, Nuermberger E, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S102-S109.

36.

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101.

37.

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S88-S94.

38.

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.

Deshpande D, Srivastava S, Pasipanodya JG, Bush SJ, Nuermberger E, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S80-S87.

39.

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.

Srivastava S, Deshpande D, Pasipanodya JG, Thomas T, Swaminathan S, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S75-S79. Review.

40.

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.

Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S63-S74.

41.

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism.

Rogers Z, Hiruy H, Pasipanodya JG, Mbowane C, Adamson J, Ngotho L, Karim F, Jeena P, Bishai W, Gumbo T.

EBioMedicine. 2016 Sep;11:118-126. doi: 10.1016/j.ebiom.2016.07.031. Epub 2016 Jul 27.

42.

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.

43.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

44.

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.

Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5922-7. doi: 10.1128/AAC.00961-16. Print 2016 Oct.

45.

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C.

BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.

46.

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.

Deshpande D, Srivastava S, Musuka S, Gumbo T.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4652-8. doi: 10.1128/AAC.02985-15. Print 2016 Aug.

47.

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.

Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T.

EBioMedicine. 2016 Apr;6:126-138. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27.

48.

Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 May 23;60(6):3779-85. doi: 10.1128/AAC.02821-15. Print 2016 Jun.

49.

Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.

Srivastava S, van Rijn SP, Wessels AM, Alffenaar JW, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3193-5. doi: 10.1128/AAC.02924-15. Print 2016 May.

50.

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2895-900. doi: 10.1128/AAC.03112-15. Print 2016 May.

Supplemental Content

Support Center